아르부투스 바이오파마(ABUS) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 아르부투스 바이오파마(ABUS)?

아르부투스 바이오파마(ABUS) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of ABUS?

The market cap of ABUS is approximately $871M, ranking 2,754 within its sector.

Q: What is the P/E ratio of ABUS?

ABUS has a P/E ratio of approximately 5.4x, which can be used to assess its valuation relative to the Healthcare sector average.

Q: What is the 52-week high and low for ABUS?

ABUS has recorded a 52-week high of $5.38 and a low of $3.19.

ABUS

Arbutus Biopharma Corp

7월 27일 4:00 PM ET (한국 7/28 05:00)

$4.41

+0.03 ▲ +0.68%

🌙 7월 27일 7:41 PM ET (한국 7/28 08:41)

$4.49

+0.08 ▲ +1.80%

아르부투스 바이오파마(ABUS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$871M

스몰캡

P/E

5.4

저평가 구간

배당수익률

없음

52주 위치

56%

저점 +38% · 고점 -18%

애널리스트

적극 매수

Fundamental health

vs. Biotechnology 소형주

수익성

Top 1%

성장

Top 29%

밸류에이션

Top 71%

재무 안정

Top 23%

Index ⓘ	RUT	P/E ⓘ	5.36	EPS (ttm) ⓘ	0.82	Insider Own ⓘ	20.46%	Shs Outstand ⓘ	196.9M	Perf Week ⓘ	-
Market Cap ⓘ	0.87B	Forward P/E ⓘ	-	EPS next Y ⓘ	-112.26%	Insider Trans ⓘ	-	Shs Float ⓘ	157.1M	Perf Month ⓘ	-
Enterprise Value ⓘ	0.78B	PEG ⓘ	-	EPS next Q ⓘ	-0.02	Inst Own ⓘ	66.69%	Short Float ⓘ	12.51%	Perf Quarter ⓘ	5%
Income ⓘ	0.16B	P/S ⓘ	4.55	EPS this Y ⓘ	541.77%	Inst Trans ⓘ	0.25%	Short Ratio ⓘ	9.79	Perf Half Y ⓘ	8.62%
Sales ⓘ	0.19B	P/B ⓘ	3.34	EPS next 5Y ⓘ	-	ROA ⓘ	81.55%	Short Interest ⓘ	19.65M	Perf YTD ⓘ	-8.32%
Book/sh ⓘ	1.32	P/C ⓘ	9.15	EPS past 3/5Y ⓘ	27.58% 29.45%	ROE ⓘ	94.73%	52W High ⓘ	-18.03% ($5.38)	Perf Year ⓘ	36.96%
Cash/sh ⓘ	0.48	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-28.8% 15.29%	ROIC ⓘ	61%	52W Low ⓘ	38.03% ($3.19)	Perf 3Y ⓘ	106.07%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	5.03	EPS Y/Y TTM ⓘ	305.12%	Gross Margin ⓘ	99.98%	Volatility(W/M) ⓘ	4.36% 4.98%	Perf 5Y ⓘ	63.33%
Dividend TTM ⓘ	-	EV/Sales ⓘ	4.07	Sales Y/Y TTM ⓘ	2889.93%	Oper. Margin ⓘ	81.01%	ATR (14) ⓘ	0.21	Perf 10Y ⓘ	4.01%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	54.26	EPS Q/Q ⓘ	775.97%	Profit Margin ⓘ	83.95%	RSI (14) ⓘ	44.53	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	54.26	Sales Q/Q ⓘ	10054.54%	SMA20 ⓘ	-6.22% ($4.7)	Beta ⓘ	0.65	Target Price ⓘ	$5.5
Payout ⓘ	-	Debt/Eq ⓘ	0.02	Earnings ⓘ	2026/5/13	SMA50 ⓘ	-2.25% ($4.51)	Rel Volume ⓘ	0.49	Prev Close ⓘ	$4.38
Employees ⓘ	19	LT Debt/Eq ⓘ	0.01	EPS/Sales Surpr. ⓘ	3000% 23783.47%	SMA200 ⓘ	-0.81% ($4.45)	Avg Volume(3M) ⓘ	2.01M	Price ⓘ	$4.41
IPO ⓘ	2007/7/23	Option/Short ⓘ	Yes/Yes			Trades ⓘ	5877	Volume ⓘ	977,633	Change ⓘ	0.68%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $179M (YoY +10055%) · 순이익 $170M (YoY +792%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Arbutus Biopharma Corp (ABUS) Investment Analysis

What kind of company is Arbutus Biopharma Corp?

아르부투스 바이오파마(ABUS) 방어주

Healthcare · Biotechnology

Healthcare Stocks

🧬 Arbutus Biopharma is a clinical-stage biotech company with the goal of curing chronic hepatitis B, trading under the ticker ABUS. It pursues a functional cure by combining an RNAi-based foundational drug with an oral immunomodulator, and leverages its deep virology expertise as a core competitive advantage.

Learn more about Arbutus Biopharma Corp →

Market Cap

$0.9B

Approx. KRW 1.2 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank2754

Employees19people

IPO2007/07/23

Current Price$4.41 ≈ 6,042원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 13일 (수) · 장 시작 전 EPS +3000.0% 매출 +23783.5%

🔔 Earnings release 2026년 3월 23일 (월) · 장 시작 전 EPS +71.5% 매출 +71.0%

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

81.0%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 소형주 Median -210.9% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

84.0%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 소형주 Median -187.6% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

100.0%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 소형주 Median 84.9% · Top 8%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

94.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -37.5% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

81.5%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -21.8% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

61.0%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -25.0% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.02

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

54.26

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

54.26

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$5.50

현재가 대비 +24.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-112.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+1172.8%

평균 서프라이즈

2026.05.13

상회

실적 $1.19 · 예상 $-0.06 +2270.6%

2026.03.23

상회

실적 $-0.01 · 예상 $-0.06 +75.1%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+541.8%

우수

My positionTop 5%

Low range Average High range

방어주 소형주 Median 4.7% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-112.3%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 소형주 Median 10.1% · Bottom tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+27.6%

양호

My positionMid-range

Low range Average High range

방어주 소형주 Median 16.1% · Top 32%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+29.4%

우수

My positionTop 25%

Low range Average High range

방어주 소형주 Median 8.7% · Top 18%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+15.3%

우수

My positionTop 25%

Low range Average High range

방어주 소형주 Median 6.7% · Top 24%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+10054.5%

우수

My positionTop 5%

Low range Average High range

방어주 소형주 Median 4.9% · Top tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 5%p over 5 years

ABUS +63.3% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-5.0%p

slightly behind the market

vs Health Care (XLV)

+38.8%p

well ahead of the sector average

1-year basis

vs S&P 500

+20.9%p

ahead of the market

vs Health Care (XLV)

+17.2%p

ahead of the sector average

Rank among peers

5-year return Top among peers Based on 123 peers

1-year return Lower-Mid (lower 46%) Based on 154 peers

Current position within 52-week range

Low (-38.0%p) High (-18.0%p)

Current price is 38.0% above the 52-week low and 18.0% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-16.9%

Annualized volatility

43.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $4.41 below the midline ($4.70). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.041 < Signal 0.015 in negative zone + Hist negative (-0.056). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 44.6 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 14.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

5.36x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 7.65x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

3.34x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 3.34x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

4.55x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 14.61x · Top 22% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

5.03x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 19.26x · Top 11% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

Analyst target price (reference)

$5.50 vs. current price +24.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow shows some pressure

Institutional modest net buying +0.3% · Short interest elevated 12.5% · Short interest up +2.7pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+0.3%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 66.7%

Adequate institutional weight

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 20.5%

Founder/management large holders (strong skin-in-the-game)

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 12.8%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

12.5%

Somewhat high

Healthcare 소형주 Median 11.2%

Past 90 days 📈 +2.7%p increase

Short interest days to cover

9.8 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 196.9M주

Float (tradable shares) 157.1M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ABUS

ETFs with the highest weightings · 10 total shown

BBC

Virtus Biotech Clinical Trials ETF

0.66%

$47M

QQQS

Invesco NASDAQ Future Gen 200 ETF

0.50%

$21M

XBI

State Street SPDR S&P Biotech ETF

0.14%

$10.0B

IWC

iShares Micro-Cap ETF

0.14%

$1.4B

KOMP

State Street SPDR S&P Kensho New Economies Composite ETF

0.12%

$2.6B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ABUS This Stock	$871.1M	5.4 ▲	3.3 ▼	94.73% ▲	-	+0.7%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 아르부투스 바이오파마(ABUS)?

아르부투스 바이오파마(ABUS) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ABUS?

The market cap of ABUS is approximately $871M, ranking 2,754 within its sector.

What is the P/E ratio of ABUS?

ABUS has a P/E ratio of approximately 5.4x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for ABUS?

ABUS has recorded a 52-week high of $5.38 and a low of $3.19.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.